

# TCF1/TCF7 Blocking Peptide

**Orders** ■ 877-616-CELL (2355)  
orders@cellsignal.com

**Support** ■ 877-678-TECH (8324)  
info@cellsignal.com

**Web** ■ www.cellsignal.com

rev. 06/02/17

**For Research Use Only. Not For Use In Diagnostic Procedures.**

**Description:** This peptide is used to block TCF1/TCF7 (C63D9) Rabbit mAb #2203 reactivity in peptide dot blot protocols.

**Background:** LEF1 and TCF are members of the high mobility group (HMG) DNA binding protein family of transcription factors which consists of the following: Lymphoid enhancer factor 1 (LEF1), T Cell Factor 1 (TCF1/TCF7), TCF3/TCF7L1 and TCF4/TCF7L2 (1). LEF1 and TCF1/TCF7 were originally identified as important factors regulating early lymphoid development (2) and act downstream in Wnt signaling. LEF1/TCF bind to Wnt response elements to provide a docking site for  $\beta$ -catenin, which translocates to the nucleus to promote the transcription of target genes upon activation of Wnt signaling (3). LEF1/TCF proteins are dynamically expressed during development and aberrant activation of the Wnt signaling pathway is involved in many types of cancers including colon cancer (4,5).

**Quality Control:** The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks TCF1/TCF7 (C63D9) Rabbit mAb #2203 by peptide dot blot.

**Directions for Use:** Recommended antibody dilutions can be found on the relevant product data sheet.

**Storage:** Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA and 5% glycerol. 1% DMSO Store at -20°C.

#### Background References:

- (1) Waterman, M.L. (2004) *Cancer Metastasis Rev.* 23, 41–52.
- (2) Schilham, M.W. and Clevers, H. (1998) *Semin. Immunol.* 10, 127–132.
- (3) Brantjes, H. et al. (2002) *Biol. Chem.* 383, 255–261.
- (4) Reya, T. and Clevers, H. (2005) *Nature* 434, 843–850.
- (5) Logan, C.Y. and Nusse, R. (2004) *Annu. Rev. Cell Dev. Biol.* 20, 781–810.